Medica Sur SA de CV Adjusts Valuation Metrics Amid Flat Financial Performance

Medica Sur SA de CV, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation that reflects changes in its valuation metrics. The company's P/E ratio stands at 12, indicating a competitive positioning within its industry. Additionally, the Price to Book Value is recorded at 2.44, while the EV to EBIT and EV to EBITDA ratios are noted at 7.50 and 5.94, respectively. The PEG ratio, which is a critical indicator of growth relative to valuation, is currently at 0.26, suggesting a favorable outlook in terms of growth potential compared to its price. Furthermore, the company boasts a robust ROCE of 38.00% and an ROE of 20.95%, highlighting effective capital utilization and shareholder returns. Despite these metrics, the company has experienced a flat financial performance in the quarter ending December 2025, with operating profit growth averaging 3.90% annually over the past five years. This context provides a comprehensive view of Medica Sur SA de CV's current standing in the market. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.